Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

• ClinicalTrials.gov Identifier: NCT03345784
• Recruitment Status: Active, not recruiting
• First Posted: November 17, 2017
• Last Update Posted: June 8, 2022
• Sponsor: National Cancer Institute (NCI)
• Information provided by (Responsible Party): National Cancer Institute (NCI)

Tracking Information

• First Submitted Date: November 16, 2017
• First Posted Date: November 17, 2017
• Last Update Posted Date: June 8, 2022
• Actual Study Start Date: October 23, 2017
• Estimated Primary Completion Date: October 26, 2022 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: April 26, 2018): Recommended phase 2 dose defined as the dose level with < 1/6 patients with dose limiting toxicities [ Time Frame: Up to week 5 ]
• Original Primary Outcome Measures (submitted: November 16, 2017): RP2D defined as the dose level with < 1/6 patients with dose limiting toxicities [ Time Frame: Up to week 5 ]

Current Secondary Outcome Measures (submitted: July 8, 2020)

• Objective response assessed according to local investigator [ Time Frame: Up to 2 years ]
  Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics.
• Pharmacodynamic effects of adavosertib when given in combination with radiation therapy and cisplatin [ Time Frame: Up to 2 years ]
  Pharmacodynamic biomarkers will include: phosphorylated (p)CDC2, Ki67, gammaH2AX, pH3, and CC3. Associations between pharmacokinetic data with toxicity profiles will be performed primarily using descriptive statistics; however, logistic regression may be used if warranted.
• Progression-free survival [ Time Frame: From start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years ]
  Summary statistics, such as the mean, median, counts and proportion, will be used to describe patients' clinical characteristics.
• Incidence of acute adverse events assessed by National Cancer Institute (NCI) Clinical Trials Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (version 5.0 beginning April 1, 2018) [ Time Frame: Up to 2 years ]
  Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Adverse events will be summarized using all adverse events experienced, although a subanalysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to one or both study treatments.
• Incidence of late adverse events assessed by NCI CTCAE version 4.0 (version 5.0 beginning April 1, 2018) [ Time Frame: Up to 2 years ]
  Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Adverse events will be summarized using all adverse events experienced, although a subanalysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to one or both study treatments.

Original Secondary Outcome Measures (submitted: November 16, 2017)

• Incidence of acute adverse events assessed by National Cancer Institute (NCI) Clinical Trials Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Up to 2 years ]
  Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Adverse events will be summarized using all adverse events experienced, although a subanalysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to one or both study treatments.
• Incidence of late adverse events assessed by NCI CTCAE version 4.0 [ Time Frame: Up to 2 years ]
  Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Adverse events will be summarized using all adverse events experienced, although a subanalysis may be conducted including only those adverse events in which the treating physician deems possibly, probably or definitely attributable to one or both study treatments.
• Objective response assessed by Response Evaluation Criteria in Solid Tumors 1.1 criteria [ Time Frame: Up to 2 years ]
• Pharmacodynamic effects of WEE1 inhibitor AZD1775 when given in combination with radiation therapy and cisplatin [ Time Frame: Up to 2 years ]
  Pharmacodynamic biomarkers will include: pCDC2, Ki67, γH2AX, pH3, and CC3. Associations between pharmacokinetic data with toxicity profiles will be performed primarily using descriptive statistics; however, logistic regression may be used if warranted.
• Progression-free survival [ Time Frame: From start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
• Official Title: A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)
• Brief Summary: This phase I trial studies the side effects and best dose of adavosertib when given together with external beam radiation therapy and cisplatin in treating patients with cervical, vaginal, or uterine cancer. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. External beam radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving adavosertib, external beam radiation therapy, and cisplatin may work better in treating patients with cervical, vaginal, or uterine cancer.

Detailed Description

PRIMARY OBJECTIVE:

I. To determine the recommended phase II dose (RP2D) and safety profile of adavosertib (AZD1775) in combination with radiotherapy and concurrent cisplatin in patients with gynecological cancers.

SECONDARY OBJECTIVES:

I. To determine the acute and late toxicity of AZD1775 when administered to patients with gynecological cancer in combination with standard radiotherapy and concurrent cisplatin.

II. To evaluate the pharmacodynamic effects of AZD1775 when administered in combination with radiotherapy and concurrent cisplatin (in particular, for the 15 patients treated in an expansion cohort at the RP2D).

III. To obtain preliminary information about the progression-free survival, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or clinical progression, of AZD1775 in combination with standard radiotherapy and concurrent cisplatin in women with gynecological cancer.

OUTLINE: This is a dose-escalation study of adavosertib.

Patients undergo external beam radiation therapy on days 1-5 and receive adavosertib orally (PO) on days 1, 3, and 5 or once daily (QD) on days 1-5 and cisplatin intravenously (IV) over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.

After completion of study treatment, patients are followed up at 28 days and then every 4 months for 2 years.

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Cervical Carcinoma
• Endometrioid Adenocarcinoma
• Malignant Female Reproductive System Neoplasm
• Recurrent Cervical Carcinoma
• Stage I Uterine Corpus Cancer AJCC v7
• Stage I Vaginal Cancer AJCC v6 and v7
• Stage IA Uterine Corpus Cancer AJCC v7
• Stage IB Cervical Cancer AJCC v6 and v7
• Stage IB Uterine Corpus Cancer AJCC v7
• Stage IB2 Cervical Cancer AJCC v6 and v7
• Stage II Cervical Cancer AJCC v7
• Stage II Uterine Corpus Cancer AJCC v7
• Stage II Vaginal Cancer AJCC v6 and v7
• Stage IIA Cervical Cancer AJCC v7
• Stage IIB Cervical Cancer AJCC v6 and v7
• Stage III Cervical Cancer AJCC v6 and v7
• Stage III Uterine Corpus Cancer AJCC v7
• Stage III Vaginal Cancer AJCC v6 and v7
• Stage IIIA Cervical Cancer AJCC v6 and v7
• Stage IIIA Uterine Corpus Cancer AJCC v7
• Stage IIIB Cervical Cancer AJCC v6 and v7
• Stage IIIB Uterine Corpus Cancer AJCC v7
• Stage IIIC Uterine Corpus Cancer AJCC v7
• Vaginal Carcinoma

Intervention

• Drug: Adavosertib
  Given PO
• Drug: Cisplatin
  Given IV
• Radiation: External Beam Radiation Therapy
  Undergo external beam radiation therapy

Study Arms

Experimental: Treatment (radiation therapy, adavosertib, cisplatin)

Patients undergo external beam radiation therapy on days 1-5 and receive adavosertib PO on days 1, 3, and 5 or QD on days 1-5 and cisplatin IV over 1 hour on day 1 or 3. Cycles repeat each week for up to 5 weeks in the absence of disease progression of unacceptable toxicity.

Interventions:

• Drug: Adavosertib
• Drug: Cisplatin
• Radiation: External Beam Radiation Therapy

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Estimated Enrollment (submitted: April 26, 2018): 33
• Original Estimated Enrollment (submitted: November 16, 2017): 24
• Estimated Study Completion Date: October 26, 2022
• Estimated Primary Completion Date: October 26, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Patients must have one of the following biopsy proven gynecological cancer and a decision to treat with radiotherapy and concurrent cisplatin chemotherapy (RT-CT)

  • Newly diagnosed epithelial carcinoma of the cervix, cT1B-3B, N0/1, M0/1

    • Patient may have small volume metastatic disease in para-aortic or supraclavicular lymph nodes or at other metastatic sites as long as, in the best judgment of the treatment team, a radical course of pelvic radiotherapy is warranted to assure local disease control

  • Newly diagnosed epithelial carcinoma of the upper 1/3 vagina, T1-3, N0/1, M0/1

    • Patient may have small volume metastatic disease in para-aortic or supraclavicular lymph nodes or at other metastatic sites as long as, in the best judgment of the treatment team, a radical course of pelvic radiotherapy is warranted to assure local disease control
  • Newly diagnosed endometrioid adenocarcinoma of the uterus, cT1-3, N0/1, M0 unsuitable for primary surgery because of the extent of local disease; these patients are eligible if a prior decision has been made to treat radically with neoadjuvant chemoradiation followed by surgery or further radiotherapy (including brachytherapy) depending on response
  • Central pelvis or sidewall recurrence of epithelial carcinoma of the cervix of endometrioid adenocarcinoma of the uterus after previous surgery without previous pelvic radiotherapy
• Patients must be planned to receive whole pelvic radiotherapy to a total dose of 45 Gy or greater
• Patients must be able to receive weekly cisplatin
• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Karnofsky >= 60%)
• Life expectancy of greater than 3 months
• Leukocytes >= 3,000/mcL
• Absolute neutrophil count >= 1,500/mcL
• Platelets >= 100,000/mcL

• Hemoglobin >= 9 g/dL

  • Blood transfusions are allowed at any time during the screening, treatment or follow-up period, according to the center recommendations
• Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =< 1.5 upper limit of normal (ULN)
• Total bilirubin: serum bilirubin within normal limits (WNL) or =< 1.5 x ULN in patients with liver metastases; or total bilirubin =< 3.0 x ULN with direct bilirubin WNL in patients with documented Gilbert's syndrome
• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]): Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit of normal (ULN) or =< 5 x ULN if known hepatic metastases
• Creatinine clearance (CrCl) >= 60 mL/min as calculated by the Cockcroft-Gault method
• Patients must be able to swallow whole capsules
• The effects of AZD1775 on the developing human fetus are unknown; the preclinical chromosomal aberrations assays have shown potential to induce chromosomal aberrations; in addition, cisplatin and radiotherapy are known to be teratogenic; for this reason, women of child-bearing potential must agree to use two birth control methods (two barrier methods or a barrier method plus a hormonal method) or abstinence prior to study entry, for the duration of study participation prior to study entry, for the duration of study participation, and for 4 months after coming off study; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately
• Females with child-bearing potential must have had a negative serum pregnancy test result =< 28 days prior to the first dose of study treatment
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Patients who have received any radiotherapy or chemotherapy for their current gynecological cancer
• Patients who received prior pelvic radiotherapy for any indication
• Patients who have a mean resting correct corrected QT (QTc) interval using the Fridericia formula (QTcF) > 470 msec (as calculated per institutional standards) obtained from 3 electrocardiograms (ECGs) 2-5 minutes apart at study entry, or congenital long QT syndrome; AZD1775 should not be given to patients who have a history of Torsades de pointes unless all risk factors contributed to Torsades have been corrected; AZD1775 has not been studied in patients with ventricular arrhythmias or recent myocardial infarction
• Patients requiring para-aortic radiotherapy
• Patients who are receiving any other investigational agents or anticancer therapy concurrently or within 4 weeks (i.e. 28 days)
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD1775 or cisplatin
• Uncontrolled intercurrent illness including, but not limited to, myocardial infarction within 6 months, congestive heart failure, symptomatic congestive heart failure, unstable angina pectoris, active cardiomyopathy, unstable ventricular arrhythmia, uncontrolled hypertension, uncontrolled psychotic disorders, serious infections, active peptic ulcer disease, active liver disease or cerebrovascular disease with previous stroke, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant women are excluded from this study because AZD1775 and chemoradiation are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with AZD1775 and cisplatin, breastfeeding must be discontinued if the mother is treated with AZD1775 and cisplatin; these potential risks may also apply to other agents used in this study
• Patients with another uncontrolled malignancy; patients with a previous malignancy, treated curatively and without evidence of disease relapse are eligible
• Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AZD1775; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
• History of active clinically significant bleeding
• History of bowel obstruction or malabsorption syndromes (within the last 3 months) which might limit the absorption of the study drug

Sex/Gender

• Sexes Eligible for Study: Female

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, United States

Administrative Information

• NCT Number: NCT03345784
• Other Study ID Numbers: NCI-2017-00038; NCI-2017-00038 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); 2013-01765; PHL-087; 10132 ( Other Identifier: University Health Network Princess Margaret Cancer Center LAO ); 10132 ( Other Identifier: CTEP ); UM1CA186644 ( U.S. NIH Grant/Contract )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: National Cancer Institute (NCI)
• Original Responsible Party: Same as current
• Current Study Sponsor: National Cancer Institute (NCI)
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Stephanie Lheureux; University Health Network Princess Margaret Cancer Center LAO

• PRS Account: National Cancer Institute (NCI)
• Verification Date: April 2022